Ahsan Bhatti, superintendent pharmacist at UK online pharmacy Quick Meds, explains what the newly approved Wegovy tablet means for patients considering injectable weight loss treatments.
The approval of the first oral GLP-1 treatment in the UK marks a significant change in how obesity can be managed in the coming years. Until now, drugs like Wegovy were only available as injections. The advent of a tablet version changes this landscape, offering a new option for both patients and non-patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) has now approved oral semaglutide for weight management in adults living with obesity or those with at least one weight-related condition. It contains the same active ingredient used in the Wegovy injection pen, which is designed to regulate appetite by mimicking the body’s natural hormone GLP-1, which helps control hunger and fullness.
In simple terms, it works via the same injectable biologic route, but in a daily tablet rather than a weekly injection.
For many patients, this is all that matters. Needle-free therapy removes one of the most common barriers I see in practice: reluctance or anxiety around injections. This can open the door for people who have previously refused treatment, even when clinically appropriate.
For those already using GLP-1 injections, the tablet is an option rather than a replacement. Some patients may prefer the idea of a daily regimen to a weekly injection, while others who are persistent in treatment will likely stick with what already works for them. What is clear is that clinicians now have more flexibility to tailor treatment to preferences and lifestyle.
However, the tablet is not only a convenient injection option. Oral semaglutide has strict dosage requirements to be properly absorbed, typically taken on an empty stomach with water, followed by a waiting period before meals. In practice, this means that routine and discipline are as important as the drug itself.
Clinical trial data supporting regulatory approval show that oral semaglutide can achieve significant weight loss when used with diet and lifestyle changes. Although injectable GLP-1 therapy may still offer slightly higher or more consistent results in some cases, the overall effectiveness is broadly comparable, especially when patients adhere to the treatment properly.
Side effects are similar in both forms, especially when the dose is increased. Nausea, constipation, diarrhea and abdominal discomfort are more commonly reported, although these will improve over time as the body adjusts.
From a broader healthcare perspective, this approval is likely to increase demand significantly. Patients who were hesitant before can now consider treatment, while private clinics and pharmacies must adapt to the growing interest in GLP-1 therapy.
The NHS should also assess how oral semaglutide compares to existing weight management options, including cost-effectiveness and preference over injectable options. But for patients, the arrival of the Wegovy tablet finally means more choice.
For more information on Quick Meds, visit https://www.quickmeds.co.uk/online-clinic/weight-loss/
- About the Author
- Latest news
Our editorial team are writers and experts in their field. Their views and opinions are not necessarily those of Wellbeing Magazine. If you are under medical supervision, talk to your doctor or therapist before following the advice and recommendations in this article.
